What did @adamvanspanje actually say?
The creator described CJC-1295 as a synthetic analogue of growth hormone releasing hormone (GHRH) that stimulates the body's own growth hormone production rather than replacing it directly. They cited early studies showing elevated IGF-1 and growth hormone levels persisting for up to six days after a single dose. They also mentioned stacking CJC-1295 with another peptide, referenced as a "myrrhone" (almost certainly ipamorelin, based on context), and acknowledged that most combination protocols are "based on theory and anecdotal, not high-level human trials." That last disclaimer is doing a lot of heavy lifting here, and it deserves credit.
The video closes with a referral to a specific clinic, which means this is not purely educational content. It is marketing with a disclaimer attached. Worth keeping that framing in mind as you read on.
Does the science back this up?
Partially, yes. The foundational pharmacology is accurate, but the clinical evidence thins out quickly once you move past early Phase I and II data.
The six-day elevation claim traces back to a 2006 study by Ionescu and Frohman published in The Journal of Clinical Endocrinology and Metabolism. That study examined CJC-1295 with drug affinity complex (DAC) technology in healthy adults and did show sustained GH and IGF-1 increases lasting up to six days. However, this is a small, early-phase trial. Participants numbered in the dozens, not hundreds. A 2013 review by Sigalos and Pastuszak in Sexual Medicine Reviews noted that the long-term safety profile of GHRH analogues in healthy populations remains poorly characterized.
The mechanism is solid: CJC-1295 binds GHRH receptors in the pituitary and prolongs GH pulse amplitude. That part is not disputed. What is disputed is whether the downstream effects, muscle gain, fat loss, improved sleep, translate into clinically meaningful outcomes in healthy adults at doses used outside formal trials.
What did they get wrong (or right)?
The creator gets the mechanism right and earns credit for the disclaimer about anecdotal stacking. But a few things need flagging.
First, the name "Sermorelin" was mangled into "Sermerelline," which matters because Sermorelin is an FDA-approved peptide with a distinct regulatory history. CJC-1295 is not FDA-approved for any indication. Conflating them, even loosely, can mislead viewers about what has actual regulatory standing.
Second, the framing of CJC-1295 as "one of the most researched" peptides in the GHRH analogue class is overstated. Sermorelin has significantly more published clinical data, including long-term studies. CJC-1295 has a handful of trials, mostly early-phase, mostly small.
- What they got right: the basic GHRH agonist mechanism and the six-day duration claim from the Ionescu 2006 data.
- What they got wrong: calling it "one of the most researched," misnaming Sermorelin, and not flagging that CJC-1295 is not approved by the FDA or TGA for general use.
- What they left out: any discussion of risks, including potential effects on insulin sensitivity, IGF-1-driven cell proliferation concerns, or the legal status of compounded peptides.
What should you actually know?
CJC-1295 is a pharmacologically interesting compound with a plausible mechanism, early human data supporting GH and IGF-1 elevation, and almost no long-term safety data in the populations using it most: healthy adults chasing body composition or recovery goals.
The risk conversation is largely absent from this video. Chronically elevated IGF-1 has been associated with increased proliferative signaling in pre-clinical models. That does not mean CJC-1295 causes cancer, but it does mean you should not dismiss the question. A 2019 review by Laron in Endocrine Practice raised concerns about long-term IGF-1 elevation in non-deficient adults, though direct causality has not been established in human trials.
In Australia, where this clinic operates, peptides including CJC-1295 are generally Schedule 4 prescription medicines under the TGA framework. That means a licensed prescriber needs to be involved, and compounded formulations carry their own quality and consistency considerations. Anyone considering this should have blood work done first, including baseline IGF-1, and should work with a provider who knows how to interpret those results, not just someone selling a protocol.